



¹ Emergency and Intensive Care Medicine, HUMANITAS Gradenigo Hospital; Laboratory of Diabetology and Metabolism, Department of Medical Sciences, Città della Salute, University of Turin, Italy

² Laboratory of Diabetology and Metabolism, Department of Medical Sciences, University of Turin

³ Clinical Biochemistry, Laboratory of Diabetology and Metabolism, Department of Medical Sciences, University of Turin

Correspondence to: G Musso
giovanni_musso@yahoo.it

Cite this as: *BMJ* 2020;371:m4147

<http://dx.doi.org/10.1136/bmj.m4147>

Published: 12 November 2020

ADVERSE DRUG REACTIONS

Diabetic ketoacidosis with SGLT2 inhibitors

Giovanni Musso,¹ Francesca Saba,² Maurizio Cassader,³ Roberto Gambino³

What you need to know

- Sodium-glucose cotransporter-2 (SGLT2) inhibitors are relatively new drugs approved for diabetes, but they increase the risk for diabetic ketoacidosis, particularly in patients with type 1 diabetes and those with certain high risk conditions
- In some cases blood glucose levels are normal or only mildly elevated, a condition known as euglycaemic ketoacidosis, which can delay the diagnosis
- Check ketones in patients taking SGLT2 inhibitors with symptoms or precipitating factors for ketoacidosis regardless of blood glucose levels

A 45 year old woman with type 2 diabetes complains of malaise, shortness of breath, and nausea for two days. She has been taking metformin and insulin. She was started on canagliflozin six weeks earlier to improve glycaemic control. Over the previous week she has halved the insulin dose. On examination, she is drowsy. Her respiratory rate is 28 breaths/min with a deep breathing pattern. A random blood glucose test shows 8 mmol/L (144 mg/dL). Blood tests reveal metabolic acidosis with an increased anion gap of 23 mmol/L (reference range 8-12 mmol/L), pH 7.18, and bicarbonate 14 mmol/L. Urine dipstick showed ketones +++.

Sodium-glucose cotransporter-2 (SGLT2) inhibitors, used in patients with diabetes, can cause diabetic ketoacidosis. This is rare but can be serious and life threatening. The US Food and Drug Administration (FDA) and European Medicines Agency (EMA) warn about possible “atypical” presentation of diabetic ketoacidosis with SGLT2 inhibitors^{1,2}: instead of having hyperglycaemia, patients may have normal or only mildly elevated blood glucose levels (<13.9 mmol/L, <250 mg/dL). This may delay diagnosis. In 2020, the FDA and EMA updated guidance to interrupt SGLT2 inhibitors and monitor ketosis in patients scheduled for surgery or hospitalised.^{3,4}

What are SGLT2 inhibitors?

SGLT2 inhibitors, also called gliflozins, lower blood sugars by causing kidneys to remove glucose from the body in urine.⁵ Figure 1 depicts their actions. They are used as second or third line therapy in type 2 diabetes along with metformin, sulfonylurea, or insulin to improve glycaemic control.⁶ In 2019, consensus guidelines in the US and Europe further recommended their use in patients with type 2 diabetes and established cardiovascular disease or chronic kidney disease.^{5,7} SGLT2 inhibitors represented 14% of new second line prescriptions and 27% of new third line prescriptions for type 2 diabetes in primary care in the UK in 2016.⁸

This is one of a series of occasional articles to help doctors prevent, diagnose, and respond to adverse drug reactions that may be serious if not recognised. The series advisers are Robin Ferner, honorary professor of clinical pharmacology, University of Birmingham and City Hospital Birmingham, and Patricia McGettigan, reader in clinical pharmacology and medical education, Queen Mary University of London.




Fig 1 | Actions of SGLT2 inhibitors in ketoacidosis. SGLT2 inhibitors inhibit SGLT2 on pancreatic islet α -cells and directly stimulate glucagon secretion, which up-regulates endogenous glucose production, ketogenesis, and lipolysis. In the kidney, SGLT2 inhibition increases ketone reabsorption. SGLT2 inhibition-induced glycosuria lowers blood glucose, thereby allowing insulin dose reduction. Insulin reduction further reduces the insulin:glucagon ratio, a critical factor in inhibiting hepatic ketogenesis and lipolysis of free fatty acids. Glycosuria also induces osmotic diuresis and dehydration, which triggers the synthesis of glucagon, cortisol, and adrenaline, further contributing to lipolysis and ketogenesis

Few SGLT2 inhibitors have been approved for type 1 diabetes in Europe and Japan as an adjunct to insulin to improve glycaemic control. The FDA has rejected their use in type 1 diabetes because of a higher risk of diabetic ketoacidosis in these patients.^{9 10} Supplementary table 1 on [bmj.com](http://www.bmj.com) lists indications and licensing for SGLT2 inhibitors.

How do patients with this adverse reaction present?

Symptoms of diabetic ketoacidosis include excessive thirst, frequent urination, dehydration, nausea, vomiting, abdominal pain, shortness of breath, and altered sensorium.^{11–14} Patients may report malaise, dizziness, and syncope, with or without fever, which are non-specific.¹⁵

Diabetic ketoacidosis is typically characterised by hyperglycaemia. Over a third of patients with ketoacidosis associated with SGLT2 inhibitor have normal or only mildly elevated blood glucose levels (<13.9 mmol/L, <250 mg/dL), also referred to as euglycaemic diabetic ketoacidosis.^{16 17} In such cases, the absence of hyperglycaemia and the less severe polyuria polydipsia, owing to the milder degree of hyperglycaemia-induced osmotic diuresis, can delay diagnosis.^{15 18}

How common is this adverse reaction?

The relative risk of diabetic ketoacidosis is higher in patients with type 1 diabetes. Observational studies with SGLT2 inhibitors suggest an incidence of 1.3–8.8 ketoacidosis events per 1000 patient-years in type 2 diabetes^{19–22} and 7.3 events per 1000 patients-years in type 1 diabetes.²³ The risk is higher in the first few months of initiating treatment. Between 76.8% and 85.2% of ketoacidosis events occur within 180 days of starting SGLT2 inhibitors in observational studies and pharmacovigilance reports.^{15 22 24}

What is the evidence?

Supplementary table 2 on [bmj.com](http://www.bmj.com) lists epidemiological evidence linking diabetic ketoacidosis to SGLT2 inhibitors. In an analysis of 487 cases of ketoacidosis from the WHO pharmacovigilance database, ketoacidosis was more frequently reported with gliflozins than with other glucose-lowering drugs (adjusted reporting odds ratio 15.5 (95% confidence interval 12.8 to 18.7)).²⁵

A meta-analysis of 13 randomised controlled trials (5397 patients) found that SGLT2 inhibitors increased the risk of diabetic ketoacidosis in type 1 diabetes (risk ratio 4.49 (95% CI 2.88 to 6.99))¹⁵ in a dose dependent manner, with a 4.9-fold higher rate at high doses of SGLT2 inhibitors (34 events per 1000 patient-years) than with low doses (7 events per 1000 patient-years). Sotagliflozin was associated with an increased risk of ketoacidosis in type 1 diabetes (relative risk 3.93 (1.94 to 7.96)) compared with placebo in a meta-analysis (6 RCTs, 3238 patients)¹⁶: higher baseline HbA1c was associated with a lower risk of diabetic ketoacidosis, and the magnitude of basal insulin dose reduction was associated with an increased risk of diabetic ketoacidosis.

High quality evidence from a systematic review and meta-analysis (39 RCTs, 60 580 patients) suggests an increased risk of diabetic ketoacidosis with SGLT2 inhibitors in type 2 diabetes compared with placebo or other antidiabetic drugs (relative risk 2.13 (1.38 to 3.27)), with an absolute rate of 3 events per 1000 patient-years.²⁶

What factors increase the risk?

Certain conditions predispose to diabetic ketoacidosis (box 1, supplementary table 3). Over two thirds of patients who develop diabetic ketoacidosis are noted to have one of these factors in observational studies of SGLT2 inhibitors.^{20 24 27}

Box 1: Predisposing conditions and precipitating factors of diabetic ketoacidosis in patients taking SGLT2 inhibitors

Predisposing condition

- Inability or unwillingness to monitor ketone bodies
- Excessive alcohol use or illicit drug use
- Very low carbohydrate or ketogenic diet
- Pregnancy (ongoing or planned)
- Previous diabetic ketoacidosis
- Inappropriate insulin dose reduction
- SGLT2 inhibitor dose
- Insulin pump use
- Late-onset autoimmune diabetes of adulthood (LADA)

Precipitating factor

- Vomiting
- Volume depletion or dehydration
- Acute infection or illness of any sort
- Hospitalisation for surgery or acute serious medical illness
- Acute volume depletion or dehydration
- Vigorous or prolonged exercise
- Insulin pump or infusion site failure
- Travel with disruption in usual schedule or insulin regimen

How is it diagnosed?

Test patients with signs and symptoms of metabolic acidosis for ketoacidosis regardless of blood glucose level.^{1–3} The following findings indicate ketoacidosis^{11–14}:

- *Increased ketones* in blood (β -hydroxybutyrate ≥ 3 mmol/L) or urine (ketonuria ++ or higher on urine dipsticks). Blood ketone testing is preferred over urine test strips as it is more accurate for detecting onset and resolution of ketosis²⁸
- *Acidosis*—serum bicarbonate < 15 mmol/L and/or blood pH < 7.3 . An elevated serum anion gap (sum of serum chloride and bicarbonate concentrations subtracted from the serum sodium concentration) > 10 mmol/L may help rule out other causes of metabolic acidosis if blood ketone testing is unavailable.⁷

Once ketoacidosis is diagnosed, other conditions that can cause it, usually in the form of euglycaemic ketoacidosis, should be excluded. These conditions and hints for differential diagnosis are listed in supplementary table 4.

How is it managed?

In patients with suspected or confirmed ketoacidosis, stop SGLT2 inhibitors immediately. International consensus guidelines for type 1 diabetes recommend the STICH protocol (stop SGLT2 inhibitor, inject bolus insulin, consume 30 g carbohydrates, hydrate)²⁹ and the STOP diabetic ketoacidosis protocol (stop SGLT2 inhibitor, test ketones, oral ingestion of fluid and carbohydrates, protocol instructions for supplemental insulin and carbohydrates)³⁰ (see supplementary table 5 for details). Early initiation of these measures can reverse ketosis and prevent progression to diabetic ketoacidosis.^{16 24}

Avoid restarting SGLT2 inhibitors after an episode of ketoacidosis unless another cause is clearly identified and resolved.² Even so, patients remain at risk of recurrence with SGLT2 inhibitors, and other antidiabetic drugs are preferred.^{17 24}

How can the risk of harm be minimised?

Assess patients for risk factors for ketoacidosis and avoid prescribing SGLT2 inhibitors in these patients (box 1, supplementary table 3).^{6 13} Explain the risk of ketoacidosis to patients before starting treatment. Start with the lowest dose required for clinical benefit. Explain when and how to measure ketones and actions to take if ketones are elevated. Patients must regularly monitor ketones in the initial weeks of therapy, regardless of symptoms.¹⁸ SGLT2 inhibitors are better avoided in patients unable to monitor ketones. Later, individualise the frequency of ketone testing according to each patient's lifestyle and risk factors. Avoid insulin dose reduction and ask patients to check ketones with every change in insulin pump set and insulin dose. Stop SGLT2 inhibitors during acute serious medical illness and at least three days before scheduled surgery and monitor ketones after drug interruption (supplementary table 3).

Ask the patients to check ketones if they develop symptoms or precipitating factors for ketoacidosis. If ketones are elevated, they should hold the medication and promptly consult their doctor.^{29 30}

Sources and selection criteria

We searched PubMed, EMBASE, Cochrane Database of Systematic Reviews, international trial registries, and drug regulatory agencies' websites up to 15 July 2020 using the search terms "ketoacidosis, diabetic, DKA, euglycaemic diabetic ketoacidosis, euDKA, ketone, ketosis, acidosis, sodium glucose cotransporter 2 (SGLT2) inhibitors." We prioritised articles on humans, scientific society guidelines (ADA, EASD, ESC, NICE, British Diabetes Societies), expert reviews, and articles providing mechanistic insights into diabetic ketoacidosis. We included in our analysis 307 records (13 systematic reviews, 161 RCTs, 30 records from regulatory agencies, 13 consensus/guidelines 59 case series, and 31 reviews on SGLT2 inhibitor-associated diabetic ketoacidosis).

Education into practice

- When do you start a patient on sodium-glucose cotransporter-2 (SGLT2) inhibitors? What factors do you consider when choosing these drugs?
- How would you discuss the risk of diabetic ketoacidosis with a patient when starting SGLT2 inhibitors and strategies to minimise the risk?
- How do patients at your practice prescribed SGLT2 inhibitors adhere to measuring ketones?

How patients were involved in the creation of this article

We arranged a live Tweet chat with 12 patients with type 2 diabetes taking SGLT2 inhibitors for their views on an initial draft of this article. Patients emphasised that general physicians educate patients on strategies to minimise the risk for diabetic ketoacidosis and the need for providing a blood ketone meter to patients taking SGLT2 inhibitors. Based on their feedback we now highlight the importance of checking ketone levels if patients have predisposing conditions and precipitating factors for diabetic ketoacidosis, irrespective of symptoms. We are grateful for their input.

Contributors: All authors made substantial contributions to the text and were involved in drafting and revision of the work and in final approval. All authors accept responsibility for the accuracy and integrity of the work. GM is the guarantor.

Competing interests: We have read and understood the BMJ policy on declaration of interests and declare the following interests: no competing interests to declare

Patient consent: Not required (patient anonymised, dead, or hypothetical).

Provenance and peer review: Commissioned, based on an idea from the author; externally peer reviewed.

- 1 US Food and Drug Administration. FDA warns that SGLT2 inhibitors for diabetes may result in a serious condition of too much acid in the blood. 2015. <https://www.fda.gov/media/92185/download>.
- 2 European Medicines Agency. EMA confirms recommendations to minimise ketoacidosis risk with SGLT2 inhibitors for diabetes. 2016. https://www.ema.europa.eu/en/documents/referral/sgl2-inhibitors-article-20-procedure-ema-confirms-recommendations-minimise-ketoacidosis-risk-sgl2_en.pdf.
- 3 US Food and Drug Administration. FDA revises labels of SGLT2 inhibitors for diabetes to include warnings about too much acid in the blood and serious urinary tract infections. 2020. <https://www.fda.gov/drugs/drug-safety-and-availability/fda-revises-labels-sgl2-inhibitors-diabetes-include-warnings-about-too-much-acid-blood-and-serious>.
- 4 Health Products Regulatory Authority. SGLT2 inhibitors – Updated advice on monitoring ketone bodies in patients hospitalised for major surgical procedures or acute serious medical illnesses. 2019. https://www.hpra.ie/docs/default-source/default-document-library/hpra-article-in-mims-supplement_november-2019.pdf.
- 5 Buse JB, Wexler DJ, Tsapas A, et al. 2019 update to: management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). *Diabetes Care* 2020;43:487-93. doi: 10.2337/dci19-0066 pmid: 31857443
- 6 National Institute for Health and Care Excellence. Type 2 diabetes in adults: management (NICE guideline NG28): 1.6 Blood glucose management. 2019. <https://www.nice.org.uk/guidance/ng28/chapter/1-Recommendations#blood-glucose-management-2>.
- 7 Cosentino F, Grant PJ, Aboyans V, et al. ESC Scientific Document Group. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. *Eur Heart J* 2020;41:255-323. doi: 10.1093/eurheartj/ehz486 pmid: 31497854
- 8 Curtis HJ, Dennis JM, Shields BM, et al. Time trends and geographical variation in prescribing of drugs for diabetes in England from 1998 to 2017. *Diabetes Obes Metab* 2018;20:2159-68. doi: 10.1111/dom.13346 pmid: 29732725
- 9 Sanofi. FDA issues complete response letter for Zynquista (sotagliflozin). 2019. <http://www.news.sanofi.us/2019-03-22-FDA-issues-Complete-Response-Letter-for-Zynquista-TM-sotagliflozin>
- 10 AstraZeneca. Update on US regulatory decision for Farxiga in type-1 diabetes. 2019. <https://www.astrazeneca.com/media-centre/press-releases/2019/update-on-us-regulatory-decision-for-farxiga-in-type-1-diabetes-15072019.html>
- 11 Agiostratidou G, Anhalt H, Ball D, et al. Standardizing clinically meaningful outcome measures beyond HbA1c for type 1 diabetes: a consensus report of the American Association of Clinical Endocrinologists, the American Association of Diabetes Educators, the American Diabetes Association, the Endocrine Society, JDRF International, The Leona M and Harry B Helmsley Charitable Trust, the Pediatric Endocrine Society, and the T1D Exchange. *Diabetes Care* 2017;40:1622-30. doi: 10.2337/dci17-1624 pmid: 29162582
- 12 Joint British Diabetes Societies Inpatient Care Group. The management of diabetic ketoacidosis in adults. 2nd ed. 2013. http://www.diabetologists-abcd.org.uk/JBDS_IP_DKA_Adults_Revised.pdf.
- 13 Handelsman Y, Henry RR, Bloomgarden ZT, et al. American Association of Clinical Endocrinologists and American College of Endocrinology position statement on the association of SGLT2 inhibitors and diabetic ketoacidosis. *Endocr Pract* 2016;22:753-62. doi: 10.4158/EP161292.PS pmid: 27082665
- 14 National Institute for Health and Care Excellence. Diabetes (type 1 and type 2) in children and young people: diagnosis and management (NICE guideline NG18): 1.4 Diabetic ketoacidosis. 2016. <https://www.nice.org.uk/guidance/ng18/chapter/1-Recommendations#diabetic-ketoacidosis-2>.
- 15 Li K, Xu G. Safety and efficacy of sodium glucose co-transporter 2 inhibitors combined with insulin in adults with type 1 diabetes: A meta-analysis of randomized controlled trials. *J Diabetes* 2019;11:645-55. doi: 10.1111/1753-0407.12890 pmid: 30565398
- 16 Musso G, Gambino R, Cassader M, Paschetta E. Efficacy and safety of dual SGLT 1/2 inhibitor sotagliflozin in type 1 diabetes: meta-analysis of randomised controlled trials. *BMJ* 2019;365:l1328. doi: 10.1136/bmj.l1328 pmid: 30967375
- 17 US Food and Drug Administration. Material for FDA presentations for the January 17, 2019 Meeting of the Endocrinologic and Metabolic Drugs Advisory Committee. <https://www.fda.gov/advisory-committees/endocrinologic-and-metabolic-drugs-advisory-committee/2019-meeting-materials-endocrinologic-and-metabolic-drugs-advisory-committee>.
- 18 European Medicines Agency. Forxiga (dapagliflozin): Product information. www.ema.europa.eu/en/documents/product-information/forxiga-epar-product-information_en.pdf.
- 19 Fralick M, Schneeweiss S, Paterno E. Risk of diabetic ketoacidosis after initiation of an SGLT2 inhibitor. *N Engl J Med* 2017;376:2300-2. doi: 10.1056/NEJMc1701990 pmid: 28591538
- 20 Wang Y, Desai M, Ryan PB, et al. Incidence of diabetic ketoacidosis among patients with type 2 diabetes mellitus treated with SGLT2 inhibitors and other antihyperglycemic agents. *Diabetes Res Clin Pract* 2017;128:83-90. doi: 10.1016/j.diabres.2017.04.004 pmid: 28448895
- 21 Ueda P, Svanström H, Melbye M, et al. Sodium glucose cotransporter 2 inhibitors and risk of serious adverse events: nationwide register based cohort study. *BMJ* 2018;363:k4365. doi: 10.1136/bmj.k4365 pmid: 30429124
- 22 Wang L, Voss EA, Weaver J, et al. Diabetic ketoacidosis in patients with type 2 diabetes treated with sodium glucose co-transporter 2 inhibitors versus other antihyperglycemic agents: An observational study of four US administrative claims databases. *Pharmacoepidemiol Drug Saf* 2019;28:1620-8. doi: 10.1002/pds.4887 pmid: 31456304
- 23 Hamp C, Swain RS, Horgan C, et al. Use of sodium-glucose cotransporter 2 inhibitors in patients with type 1 diabetes and rates of diabetic ketoacidosis. *Diabetes Care* 2020;43:90-7. doi: 10.2337/dci19-1481 pmid: 31601640
- 24 Peters AL, Buschur EO, Buse JB, Cohan P, Diner JC, Hirsch IB. Euglycemic diabetic ketoacidosis: a potential complication of treatment with sodium-glucose cotransporter2 inhibition. *Diabetes Care* 2015;38:1687-93. doi: 10.2337/dci15-0843 pmid: 26078479
- 25 Ado Mounouni AN, Robin P, Hillaire-Buys D, Faillie JL. SGLT-2 inhibitors and ketoacidosis: a disproportionality analysis in the World Health Organization's adverse drug reactions database. *Fundam Clin Pharmacol* 2018;32:216-26. doi: 10.1111/fcp.12334 pmid: 29144574
- 26 Liu J, Li L, Li S, et al. Sodium-glucose co-transporter-2 inhibitors and the risk of diabetic ketoacidosis in patients with type 2 diabetes: A systematic review and meta-analysis of randomized controlled trials. *Diabetes Obes Metab* 2020;22:1619-27. doi: 10.1111/dom.14075 pmid: 32364674
- 27 Blau JE, Tella SH, Taylor SI, Rother KI. Ketoacidosis associated with SGLT2 inhibitor treatment: analysis of FAERS data. *Diabetes Metab Res Rev* 2017;33. doi: 10.1002/dmrr.2924 pmid: 28736981
- 28 Dhatariya K. Blood ketones: measurement, interpretation, limitations, and utility in the management of diabetic ketoacidosis. *Rev Diabet Stud* 2016;13:217-25. doi: 10.1900/RDS.2016.13.217 pmid: 28278308
- 29 Danne T, Garg S, Peters AL, et al. International consensus on risk management of diabetic ketoacidosis in patients with type 1 diabetes treated with sodium-glucose cotransporter (SGLT) inhibitors. *Diabetes Care* 2019;42:1147-54. doi: 10.2337/dci18-2316 pmid: 30728224
- 30 Goldenberg RM, Gilbert JD, Hramiak IM, Woo VC, Zinman B. Sodium-glucose co-transporter inhibitors, their role in type 1 diabetes treatment and a risk mitigation strategy for preventing diabetic ketoacidosis: The STOP DKA Protocol. *Diabetes Obes Metab* 2019;21:2192-202. doi: 10.1111/dom.13811 pmid: 31183975